The U.S. Food and Drug Administration (FDA) revised the boxed warning on the label for Metformin Hydrochloride Extended Release on July 7, 2026. This revision updates critical safety information regarding the risk of lactic acidosis associated with the drug.
Background
Metformin Hydrochloride Extended Release is a medication used in the management of certain conditions. The boxed warning emphasizes the severe and potentially fatal risk of lactic acidosis, a known adverse event associated with metformin. Postmarketing cases of metformin-associated lactic acidosis have been reported, leading to serious outcomes. These outcomes include death, hypothermia, hypotension, and resistant bradyarrhythmias. The presence of a boxed warning, also known as a black box warning, is the strongest warning that the FDA requires for prescription drugs, indicating serious or life-threatening risks.
What this means
The updated boxed warning for Metformin Hydrochloride Extended Release serves to reinforce the importance of vigilance among healthcare professionals and patients regarding the potential for lactic acidosis. By detailing specific severe manifestations such as death, hypothermia, hypotension, and resistant bradyarrhythmias, the FDA aims to enhance awareness and facilitate earlier recognition and intervention for this critical adverse event. This revision underscores the need for careful patient selection, monitoring for risk factors, and prompt management strategies to mitigate the serious risks associated with metformin-associated lactic acidosis, ultimately contributing to improved patient safety.
Source
This label revision was issued by the FDA on July 7, 2026. Full details are available on the dailymed.nlm.nih.gov website.